TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29633166
Drug: Vilazodone 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 15 mg/day
Study: 29633166
Drug: Vilazodone 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 30 mg/day
Study: 30658660
Drug: BMF (Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMF (Chinese herbal medicine bi min fang)
Study: 27618925
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of penicillin V four times daily for 5 days
Study: 19835718
Drug: Drospirenone 3
Normalized name: drospirenone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 3 mg/ethinyl estradiol 20 mcg (drsp 3 mg/EE 20 mcg)
Study: 14998051
Drug: Experimental power
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental power toothbrush (twice a day brushing with Crest Cavity Protection dentifrice for 2 minutes each time)
Study: 14998051
Drug: Peroxide paint-on
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroxide paint-on gel control (Colgate Simply White Night applied once a day for the first 14 days, plus brushing twice a day with Crest Cavity Protection dentifrice for 2 minutes using ADA manual reference toothbrush)
Study: 2515593
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g b.i.d.
Study: 1882907
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g q.i.d.
Study: 6882613
Drug: alcuronium 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcuronium 0.03 mg kg‐1
Study: 6882613
Drug: tubocurarine 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: tubocurarine 0.06 mg kg‐1
Study: 6882613
Drug: pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium 0.01 mg kg‐1
Study: 28617764
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of 0.2 mL of mother's colostrum every 4 hours for 7 days
Study: 24422892
Drug: Secondary cytoreductive
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary cytoreductive surgery followed by at least six cycles of intravenous platinum-based chemotherapy
Study: 24422892
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least six cycles of intravenous platinum-based chemotherapy
Study: 17898947
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (WM group) treated with prednisone for 6 months.
Study: 12195686
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg orally prior to thrombolysis and 12 hours later
Study: 24892114
Drug: 1-stage lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-stage lateral window sinus lift with simultaneous implant placement
Study: 11218582
Drug: Ureaplasma urealyticum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ureaplasma urealyticum colonization in infants with birth weight of 1,000 g or less
Study: 9396895
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of pharmacy-prepared intravaginal prostaglandin E2 gel
Study: 31603201
Drug: EBOV GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBOV GP vaccine with Matrix‐M adjuvant (2 doses)
Study: 29924240
Drug: U-MDT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-MDT regimen (six doses of MB-MDT: rifampicin, dapsone, and clofazimine)
Study: 21541732
Drug: 2.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day CLA mixture (36.9% cis-9, trans-11 and 37.9% trans-10, cis-12)
Study: 21541732
Drug: Placebo (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.4 g olive oil/day)
Study: 21991730
Drug: Rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.3 mg kg(‐1)
Study: 19376787
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg(‐1)
Study: 14675064
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of zoledronic acid (ZOL)
Study: 2576364
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg o.d.)
Study: 7980837
Drug: Cassava-salt suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cassava-salt suspension (CSS)
Study: 2510271
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg nocte
Study: 1205340
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of heparin
Study: 1157717
Drug: Calcium heparinate
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparinate (conventional high doses)
Study: 29861395
Drug: CBDCA with
Normalized name: CBDCA
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CBDCA with nab-PTX (100 mg/m2 I.V. on days 1, 8, and 15 of each 21-day cycle)
Study: 29861395
Drug: DOC (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOC (60 mg/m2 intravenous [I.V.] on day 1)
Study: 23107038
Drug: Combination exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination exercise training
Study: 20301021
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) - sirolimus-eluting stents (SES)
Study: 27245042
Drug: Nifedipine sustained-release
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine sustained-release tablets
Study: 2664571
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg i.v./i.m. b.i.d., starting the day before the surgery for 8 days)
Study: 25807090
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 mg daily for 14 days, then 200 mg daily for 14 days)
Study: 21344260
Drug: Acetaminophen 2
Normalized name: acetaminophen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 2 g intravenously 30 min before surgery
Study: 14689227
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of contrast material (CM) at 4 ml/s followed by 40 ml of saline chaser at 4 ml/s
Study: 11870505
Drug: Cisplatin suspension
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin suspension (5 mg in 1 ml, 150 mg m(‐2), max 300 mg, max fluid 60 ml)
Study: 11870505
Drug: Usual cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual cisplatin solution (150 mg m(‐2) dissolved in 500 ml saline)
Study: 8031162
Drug: 5-FU tablets
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU tablets administered at a dose of 200 mg/day for 6 months
Study: 8031162
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone (no chemotherapy)
Study: 1832291
Drug: xipamide 20
Normalized name: xipamide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: xipamide 20 mg once daily
Study: 25970485
Drug: Combined hyperbaric
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hyperbaric (4 mg) and hypobaric (6 mg) ropivacaine (Group A)
Study: 23108937
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg, then 150 mg)
Study: 21736751
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg SC every 4 weeks
Study: 21736751
Drug: Canakinumab 300
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 300 mg SC every 2 weeks
Study: 16401655
Drug: Promethazine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 30 mg (P30)
Study: 2070977
Drug: Injection sclerosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerosis
Study: 9283858
Drug: Medical-surgical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical-surgical treatment
Study: 27484507
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training loaded with 40% of maximum inspiratory pressure, readjusted weekly
Study: 22568863
Drug: GSK1482160 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1482160 (up to 1 g, single doses)
Study: 19246793
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (400 IU twice daily)
Study: 19246793
Drug: Placebo (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard therapy only)
Study: 15719740
Drug: Shentao Ruangan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shentao Ruangan pill (SRP) combined with local perfusion of hydroxycamptothecine (HCPT)
Study: 12949315
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.5 mg (total daily dose) once or twice daily
Study: 12949315
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium nebulizer solution 20 mg 4 times daily
Study: 11986448
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension
Study: 16113791
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (0.8 mg/day) for 1 year
Study: 1850344
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.6 mg/kg/day)
Study: 31008987
Drug: Novel circumcision
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel circumcision method (subcutaneous tissue-sparing dorsal slit with new marking)
Study: 26116491
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment - High-Viscosity Glass-Ionomer Cement (ART-GIC)
Study: 21052775
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with ACNU (40 mg/m(2)/day) and CDDP (40 mg/m(2)/day) infused continuously for 72 h followed by radiotherapy and adjuvant temozolomide (150‐200 mg/m(2) for 5 days every 28 days)
Study: 2081789
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% albumin-normal saline, 10 ml/kg)
Study: 6986007
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg oxatomide b.i.d.
Study: 31752042
Drug: Routine GPI
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine GPI administration before primary PCI
Study: 31752042
Drug: Bailout GPI
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bailout GPI administration
Study: 31752042
Drug: Routine GPI
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine GPI administration
Study: 30730541
Drug: rAAV2/2-ND4 (9×109,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV2/2-ND4 (9×109, 3×1010, 9×1010, and 1.8×1011 viral genomes per eye) as a single unilateral intravitreal injection
Study: 28760390
Drug: Cigarettes (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes (CC)
Study: 25047652
Drug: Electrodiagnostic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrodiagnostic testing with physical therapy (specific interventions not detailed)
Study: 16221926
Drug: Cabergoline (DA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (DA agonist)
Study: 21544070
Drug: Methylphenidate (indirect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (indirect NE agonist)
Study: 19039224
Drug: dose fractionation
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose fractionation
Study: 15205602
Drug: Intratumoral (i.t.)
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral (i.t.) administration of cisplatin
Study: 27860389
Drug: Canrenone 50
Normalized name: canrenone
DrugBank: Canrenone (DB12221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenone 50 mg
Study: 19329547
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg LDX
Study: 9447858
Drug: High-dose ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ondansetron (150 microg/kg)
Study: 2243152
Drug: Diphenhydramine hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine hydrochloride 12.5 mg
Study: 2243152
Drug: Diphenhydramine hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine hydrochloride 25 mg
Study: 8634878
Drug: Diphenhydramine hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine hydrochloride 50 mg
Study: 2243152
Drug: Diphenhydramine hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine hydrochloride (all doses)
Study: 23453899
Drug: Low dose,
Normalized name: Aspirin Low Dose, 81 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose, metronomic cyclophosphamide + methotrexate (CM)
Study: 15356567
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg once daily (monotherapy)
Study: 15356567
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg once daily plus Montelukast 10 mg once daily (combined therapy)
Study: 15356567
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily (monotherapy)
Study: 28433798
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 250 IU/kg daily during the first 6 days of life
Study: 21971473
Drug: Cognitive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive intervention groups (IGs) receiving weekly sessions of group‐based multicomponent cognitive intervention
Study: 22516441
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg daily
Study: 14963471
Drug: PT-141 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT-141 (doses greater than 7 mg)
Study: 11898004
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment
Study: 31637444
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy plus intrathecal liposomal cytarabine (median 5 injections, range 1-20)
Study: 31637444
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy alone (control group)
Study: 31637444
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy plus intrathecal liposomal cytarabine
Study: 10527996
Drug: Trimegestone-based sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone-based sequential hormone replacement therapy (HRT) with doses of 0.05, 0.1, 0.25, and 0.5 mg per day of trimegestone from day 15 to day 28, combined with continuous micronized oestradiol 2 mg daily for six treatment cycles
Study: 7579312
Drug: Regimen 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1: rifampicin, isoniazid and pyrazinamide daily for an initial 3 months followed by rifampicin and isoniazid twice‐weekly for 6 months.
Study: 7579312
Drug: Regimen 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 2: rifampicin, isoniazid and pyrazinamide thrice‐weekly for an initial 3 months followed by rifampicin and isoniazid twice‐weekly for 6 months.
Study: 15113269
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg
Study: 7272160
Drug: Oxprenolol 80
Normalized name: oxprenolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 80 mg
Study: 7138753
Drug: Oxprenolol (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (twice a day for 2 weeks)
Study: 24420556
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and etoposide plus concurrent and sequential sorafenib 200 mg orally bid for four cycles, then 400 mg orally bid as maintenance for up to 12 months after no disease progression.
Study: 24420556
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and etoposide plus concurrent and sequential sorafenib.
Study: 3221375
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil 240 mg tablets
Study: 30786304
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg of dipyrone
Study: 19691426
Drug: Sitagliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 200 mg once daily
Study: 14612477
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg oral at 24 hours and 1-2 hours before TKA, 50 mg daily for 5 days postoperatively, and 25 mg daily for another 8 days)
Study: 9122013
Drug: Antibiotics therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics therapy
Study: 1812424
Drug: Meningococcal outer
Normalized name: Haemophilus Influenzae Type B Capsular Polysaccharide Meningococcal Outer Membrane Protein Conjugate antigen
DrugBank: Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (DB10342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal outer membrane vesicle serogroup B vaccine (MenB‐vaccine "Folkehelsa")
Study: 6615664
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg twice daily for five days)
Study: 26345529
Drug: Respiratory rehabilitation
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory rehabilitation exercise training (twice a day, 10-30 minutes per session for 4 days)
Study: 16950948
Drug: Spring dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spring dosing schedule of trivalent inactivated influenza vaccine
Study: 16950948
Drug: Fall dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fall dosing schedule of trivalent inactivated influenza vaccine
Study: 11319653
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg/day)
Study: 19368098
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification plus combinations of insulin sensitisers and insulin secretagogues
Study: 19368098
Drug: Incretin mimetics
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incretin mimetics or insulin
Study: 8857005
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of hCG (250, 500, 1000, or 2000 IU) three times a week for two weeks.
Study: 8857005
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of hCG.
Study: 8730980
Drug: Benzhexol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzhexol (5 mg)
Study: 8379601
Drug: Caffeine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (400 mg)
Study: 16142502
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 or 40 mcg/day)
Study: 17013567
Drug: Teriparatide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (40 mcg/day)
Study: 15302288
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day
Study: 15823826
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day
Study: 15823826
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 5.0 mg/day
Study: 7472662
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid supplementation (10 g/d from the 20th week of gestation until delivery)
Study: 2318517
Drug: Second drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second drug (hydralazine, methyldopa, metoprolol, or reserpine) added to hydrochlorothiazide
Study: 23694801
Drug: 1+1 hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1+1 hydromorphone titration protocol
Study: 8276647
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rate brachytherapy
Study: 8276647
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate brachytherapy
Study: 656283
Drug: Cholestyramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine treatment (about 4 g three times daily)
Study: 24491267
Drug: Chemoradiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy plus 3,500 IU daily of bemiparin for a maximum of 26 weeks